Introduction: Beijing Huamida Pharmaceutical Co., Ltd. was founded in 1995. It has developed from a private enterprise into a high-tech enterprise in Beijing, and is dedicated to the research and production of drugs for the treatment of bleeding disorders. Ramada has purchased 71 acres of industrial land in Juyuan Industrial Development Zone, Shunyi, Beijing, with a total investment of 50 million yuan in the first phase of construction. In August 2006, it passed the strict dynamic and dynamic requirements of the State Food and Drug Administration and Beijing Drug Supervision and GMP Certification Center. Static on-site inspection and certification, obtained GMP certification. Land has been reserved for the second phase of construction of solid preparations, injection production and other construction areas. At present, the total assets of the company reach 150 million yuan. At the same time, Ramada Company has independent intellectual property rights of the company, and the patented technology of Jinshu Leaf Hemostatic Mixture product has huge intangible asset value. In today's fierce market competition, enterprises have increased market development efforts and strengthened the core competitiveness of new product technologies. At the same time, in order to ensure the development needs of the enterprise in the next 10 years, they have invested in the research and development of Class I and II new drugs, allowing the enterprise to gradually develop into a A first-class company specializing in the development and production of blood disease treatment drugs, with products spread all over the world. The "Golden Potato Leaf Hemostatic Mixture" botanical medicine developed by Huameida has shown unique advantages in the treatment of idiopathic thrombocytopenic purpura, thrombocytopenia after tumor radiotherapy and chemotherapy, and bleeding diseases caused by various reasons. It has been affirmed by many experts and doctors and recognized by the medical community, and has obtained the national drug approval number: B20020440 drug approval number reviewed and approved by the State Food and Drug Administration. Huamida Company takes high-tech products as its research and production goals, GMP as its production management regulations, and has a professional scientific research team as the backing of technical support, showing an unstoppable development trend. Over the past ten years, Ramada has always taken science, innovation, development and pioneering as its business philosophy, and has made outstanding contributions to the research and development of drugs for the treatment of bleeding disorders. "Golden Potato Leaf Hemostatic Mixture" is a single-flavor plant preparation that uses a green plant as raw material and is purified using advanced modern production technology. Golden potato leaf hemostatic mixture mainly contains polysaccharides, flavonoids, more than ten kinds of amino acids, rich vitamins and trace elements necessary for the human body and other active ingredients. It has a good effect in regulating immunity, strengthening capillary permeability, bidirectionally regulating vascular permeability, increasing bone marrow cells, enhancing the phagocytic ability of macrophages, promoting megakaryocyte recovery and platelet formation and functional recovery. A large number of clinical experiments have confirmed that "Golden Potato Leaf Hemostatic Mixture" has selective affinity in the treatment of bleeding diseases and has the advantage of being able to persist in treatment, especially for idiopathic thrombocytopenic purpura, tumors after radiotherapy and chemotherapy. The treatment of thrombocytopenia is effective, and its functions are: strengthening the spleen and replenishing qi, cooling blood and stopping bleeding. It also has the effect of reducing toxicity and increasing efficacy, making it suitable for different patient groups. The perfect reputation of Ramada Pharmaceuticals is reflected in the high-tech content of its unique products. At the same time, the quality of "Golden Potato Leaf Hemostatic Mixture" is fulfilled in its commitment to patients. Ramada Pharmaceuticals will also treat related diseases in the field. We will further explore the research and development of drugs and make tireless efforts to help humans get rid of the troubles of diseases and dependence on drugs.
Legal representative: Wang Xinting
Establishment date: 1995-01-21
Registered capital: 15 million yuan
Industrial and commercial registration number ：110114004611109
Enterprise type: Limited liability company (natural person investment or holding)
Company address: No. 10, Zhongxing Road, Science and Technology Park, Changping District, Beijing